Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

GUIDE-AI GUIDE-AI – Guiding your treatment with current evidence

Coordinator
Charite - Universitaetsmedizin Berlin, Germany
Runs
1 January 2026 to 31 December 2029
Status
Running
EU funding
€4.9m
Total cost
€8.7m
Partners
19 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101253015

What the project is doing

In the project's own words, from its summary on CORDIS.

Today, chronic lung, heart, and kidney diseases constitute a large proportion of chronic illness in Europe’s population, with nearly 85% of deaths in the EU due to chronic diseases. Guideline-directed medical therapy is evidence-based and the cornerstone of pharmacological therapy for patients with chronic illness. Yet, a large number of patients are not receiving all medications as recommended given the length and complexity of guidelines.

The ambition of GUIDE-AI is to leverage generative AI to increase guideline adherence of chronically ill patients in Europe. GUIDE-AI will be developed as a blueprint on three indications: Chronic obstructive pulmonary disease, chronic heart failure, and chronic kidney disease. This setup can be expanded to other chronic diseases where clinical practice guidelines exist or be updated with the new guideline once published.

GUIDE-AI has three objectives:OBJ-A[people-centricity]: GUIDE-AI integrates the perspectives of patients, physicians, healthcare administrators, and payers, addressing both inpatient and outpatient care and covering the full treatment continuum—from diagnosis and therapy initiation to long-term monitoring and treatment adjustments. OBJ-B [Innovate & Integrate]: GUIDE-AI computer scientists and clinicians will develop the technical set-up of the guideline navigators including benchmarking and red teaming on retrospective data.

OBJ-C [evaluate in real world]: GUIDE-AI will evaluate the guideline navigators in a real-world evaluation study in a 2-arms randomized design. The primary outcomes are (1) the percentage of guideline-conform therapies and (2) the number of patients whose medication changed after the LLM-intervention. Taken together, GUIDE-AI is a public-private partnership uniquely positioned to bring together private partners with leading academic institutions to advance beyond existing solutions to increase guideline-directed medical therapy by employing generative AI, making the latest evidence actionable.

The impact will be demonstrated across multiple diseases, sectors, countries and languages.

Topics

Who is involved

OrganisationCityCountryRole
Charite - Universitaetsmedizin BerlinBerlinGermanyCoordinator
Takeda Pharmaceuticals International AGGlattparkSwitzerlandParticipant
AstraZeneca GmbHHamburgGermanyThird party
Bundesarbeitsgemeinschaft Selbsthilfe Von Menschen Mit Behinderung Und Chronischer Erkrankung Und Ihren Angehorigen E.v.DusseldorfGermanyParticipant
Ecodynamics GmbHMonheim am RheinGermanyParticipant
GlaxoSmithKline GmbH & Co. KGMunchenGermanyAssociatedpartner
Medizinische Hochschule Brandenburg Campus GmbHNeuruppinGermanyParticipant
Qurasoft GmbHKoblenzGermanyParticipant
Takeda Pharma Vertrieb GmbH & Co. KGBerlinGermanyAssociatedpartner
Tartu UlikoolTartuEstoniaParticipant
Clalit Health ServicesTel AvivIsraelParticipant
Ass Cittadinanzattiva ApsRomaItalyParticipant
AstraZeneca S.p.A.MilanoItalyAssociatedpartner
Istituti Clinici Scientifici Maugeri Societa' per Azioni Societa' BenefitPaviaItalyParticipant
Universita Degli Studi Di PaviaPaviaItalyParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Univerza V MariboruMariborSloveniaParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant
Glaxosmithkline Research & Development LimitedLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI